Target intelligence / Profile preview

Central nervous system multisynaptic pathways

Molecular classification
Other
01

Overview

Central nervous system (CNS) multisynaptic pathways are intricate networks of neurons and interneurons that facilitate the transmission and integration of signals across multiple synapses within the brain and spinal cord (StatPearls: Physiology, Reflexes). These pathways are essential for complex physiological processes, including the coordination of motor output, the processing of sensory information, and the execution of polysynaptic reflex arcs (PubMed, PMID: 11579131). In a clinical context, these pathways are often cited as the functional target for centrally acting muscle relaxants, which aim to reduce hyperactive reflex activity and muscle spasticity by depressing neuronal excitability within these circuits (Goodman & Gilman's The Pharmacological Basis of Therapeutics). The modulation of these pathways is primarily achieved through the manipulation of inhibitory neurotransmitters like gamma-aminobutyric acid (GABA) or through the inhibition of excitatory glutamatergic transmission. For instance, baclofen acts as an agonist at GABA-B receptors located on these multisynaptic circuits, while tizanidine reduces excitatory input by stimulating alpha-2 adrenergic receptors (PubChem, CID: 2284). Because the term encompasses a vast array of different neuronal types and neurotransmitter systems, it represents a physiological or anatomical system rather than a discrete molecular target like a specific receptor or enzyme. Consequently, therapeutic intervention in these pathways often results in non-specific CNS effects, including sedation, dizziness, and impaired motor coordination (NIH, National Institute of Neurological Disorders and Stroke).

Other names
Polysynaptic pathwaysCNS neuronal networksPolysynaptic reflex arcsMultisynaptic reflex pathways
02

Mechanism of action

Drugs targeting these pathways typically act by enhancing inhibitory neurotransmission (e.g., via GABA receptors) or inhibiting excitatory neurotransmission (e.g., via alpha-2 adrenergic receptors or glutamate inhibition) within the interneuronal circuits of the spinal cord and brainstem (PubMed, PMID: 15182223).

03

Biological functions

Other
04

Disease associations

Other
05

Safety considerations

SedationDizzinessMuscle weaknessRespiratory depressionPhysical dependenceWithdrawal symptoms
06

Interacting drugs

Baclofen

5 more in the full profile.

07

Biomarkers

Electromyography (EMG)H-reflexModified Ashworth Scale (MAS)F-wave latency

Beyond the preview

Go deeper on Central nervous system multisynaptic pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Central nervous system multisynaptic pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call